Craif Inc.
PrivateLast Round
Series D
Aug 18, 2026
Est. Valuation
$100M
Total Funding Raised
$77M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Craif Inc. is a biotechnology company that develops and provides exosome-based liquid biopsy tests and AI-driven diagnostic platforms for early cancer detection.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Craif Inc. Comparables
Compare Craif Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HIROTSU BIO SCIENCE INC. | 80% | |
| MiRNA Scientific | 76% | |
| Mirxes | 76% |
Craif Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 18, 2026 | ||||
| IPO | Dec 8, 2025 | ||||
| Series C | Apr 28, 2025 | ||||
| Series C | Dec 23, 2024 | ||||
| Series B Extension | Apr 12, 2022 | ||||
Series B | Nov 2, 2021 |
Key People
Founding team and executive leadership
Craif Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mori Trust Co., Ltd. | Series A |
| Tokio Marine & Nichido Fire Insurance | Series B Extension, Series B |
| Saisei Ventures | Series B Extension |
| Unreasonable Collective | Series C |
| 株式会社日本政策金融公庫 | Series D |
| Joyo Bank, Ltd. | Series D |
| Global Brain Corporation | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 18, 2026
$33M round led by TAUNS Laboratories, Inc.
- May 27, 2026
Achieved over 3x annual growth since product release in 2022.
Recent news
Latest coverage and updates
- is_developingAug 20, 2026
CRAIF Inc. is developing urine analysis platform for the early detection of multiple diseases on Jul 1st '18.
- launchesAug 18, 2026
CRAIF Inc. launches non-invasive cancer test in the.
- launchesAug 18, 2026
CRAIF Inc. launched urine-based cancer detection platform on Jul 1st '18.
- receives_financingAug 18, 2026
CRAIF Inc. received financing of $3.3M in debt on Aug 18th '26.
- hiresAug 18, 2026
CRAIF Inc. hires Nicholas (Nick) Bevins as chief medical officer.
Craif Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Craif Inc.'s valuation, stock price, and market status.
Is Craif Inc. a public or private company?
Craif Inc. is a private company.
What is the current stock price of Craif Inc.?
Craif Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Craif Inc. worth (valuation)?
Craif Inc.'s valuation is estimated at $100.0M based on funding round data.
Can I buy Craif Inc. stock?
Craif Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Craif Inc.'s last funding round?
Craif Inc.'s most recent funding round was ipo on April 28, 2025.
Who are the main investors in Craif Inc.?
Key investors in Craif Inc. include Daiwa Corporate Investment Co., Ltd., X&KSK.
Will Craif Inc. IPO soon?
No public IPO plans have been announced for Craif Inc..
How can I track Craif Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Craif Inc.'s secondary market activity and sign up for updates.